IN BRIEF: Sensyne Health gets UK heath regulator boost

Sensyne Health PLC - Oxford, England-based clinical technology using artificial intelligence - ...

Alliance News 7 May, 2021 | 6:23PM
Email Form Facebook Twitter LinkedIn RSS

Sensyne Health PLC - Oxford, England-based clinical technology using artificial intelligence - Says MagnifEyeO AI software granted Authorisation of Special Use by UK watchdog Medicines & Healthcare Products Regulatory Agency. "MagnifEye has demonstrated that it has the potential to play an important role in Covid-19 disease surveillance with increased lateral flow test reading accuracy and greater certainty over correct test interpretation," Chief Executive Officer Paul Drayson says. System uses AI to produce accurate results from lateral flow diagnostic tests.

Current stock price: 161.00 pence

Year-to-date change: up 43%

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Sensyne Health PLC

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures